CymaBay Therapeutics Reports Data From Phase 2b Study Of Seladelpar In Patients With Nonalcoholic Steatohepatitis; Reductions In Liver Fat Were Minimal, Not Significant Compared To Placebo, Reductions In Markers Of Liver Injury Were Clinically Meaningful